Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
A method of treating a patient who has glioblastoma, comprising administering to said patient a population of activated CD8+ cytotoxic T cells that kill the cancer cells that aberrantly express a peptide consisting of the amino acid sequence of AIIDGVESV (SEQ ID NO:
A method of treating a patient who has glioblastoma, comprising administering to said patient a population of activated CD8+ cytotoxic T cells that kill the cancer cells that aberrantly express a peptide consisting of the amino acid sequence of AIIDGVESV (SEQ ID NO:
A method of treating a patient who has glioblastoma, comprising administering to said patient a population of activated CD8+ cytotoxic T cells that kill the cancer cells that aberrantly express a peptide consisting of the amino acid sequence of AIIDGVESV (SEQ ID NO:
Dependencies are inferred from the claim text.